Latest Articles
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer - Insider Monkey
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer Insider Monkey
Published: June 15, 2025, 9:42 a.m.
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer - Yahoo
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer Yahoo
Published: June 15, 2025, 9:39 a.m.
Difficult childhood experiences linked to increased risk of endometriosis later in life - MSN
Difficult childhood experiences linked to increased risk of endometriosis later in life MSN
Published: June 12, 2025, 12:43 p.m.
Difficult childhood experiences linked to increased risk of endometriosis later in life - News-Medical
Difficult childhood experiences linked to increased risk of endometriosis later in life News-Medical
Published: June 11, 2025, 11:15 a.m.
Childhood Trauma May Increase Endometriosis Risk - Technology Networks
Childhood Trauma May Increase Endometriosis Risk Technology Networks
Published: June 11, 2025, 8:04 a.m.
Difficult childhood experiences may increase the risk of endometriosis - Medical Xpress
Difficult childhood experiences may increase the risk of endometriosis Medical Xpress
Published: June 11, 2025, 8 a.m.
7MM endometriosis diagnosed prevalent cases to hit 2.8 million in 2034 - Healthcare Asia Magazine
7MM endometriosis diagnosed prevalent cases to hit 2.8 million in 2034 Healthcare Asia Magazine
Published: June 11, 2025, 3:52 a.m.
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as Fir - GuruFocus
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as Fir GuruFocus
Published: June 9, 2025, 7:13 p.m.
AZN Initiates Phase 3 Trial for Enhertu in Advanced Endometrial Cancer | AZN Stock News - GuruFocus
AZN Initiates Phase 3 Trial for Enhertu in Advanced Endometrial Cancer | AZN Stock News GuruFocus
Published: June 9, 2025, 12:46 p.m.
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer - BioSpace
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer BioSpace
Published: June 9, 2025, 12:43 p.m.
Link copied to clipboard!